Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eclitasertib - Denali Therapeutics/Sanofi

Next Previous
Drug Profile

Eclitasertib - Denali Therapeutics/Sanofi

Alternative Names: DNL-758; SAR-443122

Latest Information Update: 29 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Harvard University
  • Developer Denali Therapeutics Inc; Sanofi
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antipsoriatics; Antirheumatics; Oxazepines; Pyridines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action RIPK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Ulcerative colitis
  • Discontinued Cutaneous lupus erythematosus; Psoriasis; Rheumatoid arthritis; SARS-CoV-2 acute respiratory disease

Most Recent Events

  • 25 Jul 2025 Sanofi completes a phase I bioavailability trial for Ulcerative colitis (In volunteers) in Netherlands (PO) (EudraCT2025-521073-13-00) (CTIS2025-521073-13-00)
  • 11 Jun 2025 Sanofi initiates a phase I bioavailability trial for Ulcerative colitis (In volunteers) in Netherlands (PO) (EudraCT2025-521073-13-00) (CTIS2025-521073-13-00)
  • 12 Mar 2024 Discontinued - Phase-I for Psoriasis (In volunteers) in USA (unspecified route) (Denali pipeline, February 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top